Support is requested for a Keystone Symposia conference entitled Precision Engineering of the Genome, Epigenome and Transcriptome, organized by Drs. Charles Gersbach, Rachel E. Haurwitz and Fyodor D. Urnov. The conference will be part of Keystone Symposia?s eSymposia Conference Series, which are virtual events. The dates for this online conference will be March 7-11, 2021. Over the last several years, new genome engineering tools have revolutionized the ability to interrogate biological systems, engineer innovative biotechnologies, and model and treat human disease. The genome engineering field continues to evolve at a frenzied pace, including both the development of new fundamental tools and their application to addressing societal needs. This Keystone Symposia conference will cover this spectrum of advances, including the most recent technological innovations in genome, epigenome, and transcriptome precision engineering. The conference will also highlight recent advances in developing human therapeutics with these tools, including emerging clinical trial results and preclinical examples of novel modes of intervention. The conference will include a variety of topics of interest to the broad research community, including next-generation applications such as high-throughput screening, synthetic biology, and chromatin and RNA imaging and diagnostics. Finally, the conference will conclude with examples of how emerging technologies can be integrated for an unprecedented level of resolution of cellular processes, such as genome engineering combined with single-cell analysis methods. Collectively, this meeting will build on its history of success by familiarizing the audience with the latest advances in tool development, providing an update on clinical application of these tools, and generating an appreciation for the breadth of scientific areas impacted by the Genome Engineering Revolution.
Over the last several years, new genome engineering tools have revolutionized the ability to interrogate biological systems, engineer innovative biotechnologies, as well as model and treat human disease. Researchers are now entering a crucial phase in the field?s evolution, including both the development of new fundamental tools and their application to addressing societal needs. This conference will provide a broad and timely assessment of where the field is going and how to best navigate inevitable roadblocks as researchers seek to realize the revolutionary potential of this field to address unmet medical needs across the spectrum of human disease.
